Open access peer-reviewed chapter

Deficient Autophagy Contributes to the Development of Diabetic Retinopathy

Written By

Jacqueline M. Lopes de Faria and Marcella Neves Dátilo

Submitted: 24 July 2019 Reviewed: 26 August 2019 Published: 06 November 2019

DOI: 10.5772/intechopen.89339

From the Edited Volume

The Eye and Foot in Diabetes

Edited by Jeffery Grigsby and Fethi Derbel

Chapter metrics overview

879 Chapter Downloads

View Full Metrics

Abstract

Autophagy is a self-degradation process essential to maintain intracellular homeostasis and cell survival, controlling elimination of pathogens, damage to organelles, and nutrient recycling to generate energy. Alterations in autophagic flux have been reported in the mechanisms of several diseases such as neurodegenerative diseases, cancer, diabetes mellitus, and its associated complications. Diabetic retinopathy (DR) is a microvascular complication of diabetes, affecting nearly 30% of diabetic patients. Several pathways are triggered and repressed in the development of DR, and autophagy showed to be relevant in the pathogenesis of this devastating complication. In this chapter, autophagy’s involvement in the development and progression of DR will be discussed, mainly in retinal pigmented epithelial cells and retinal microvascular endothelial cells, as well as in Müller cells—the more prominent retinal glial cell.

Keywords

  • retina
  • diabetic retinopathy
  • autophagy
  • ARPE-19
  • endothelial cell
  • Müller cell

1. Introduction

Autophagy (from Greek, meaning “self-eating”) refers to a highly conserved process in eukaryotic cells, which coordinates the degradation of intracellular components and nutrient recycling. This process is essential for cellular homeostasis, survival, and differentiation. In basal conditions, the autophagic process happens in low levels to maintain cellular homeostasis. However, in such conditions as low levels of adenosine triphosphate (ATP) or depletion of essential amino acids and glucose, autophagic flux can increase to generate energy and raise basal levels. More recently, the understanding of this process has gained attention due to its pivotal role in cellular physiology and a variety of diseases from cancer, chronic degenerative diseases, and immune diseases (Table 1).

Table 1.

In this table, some examples of genetic diseases associated with autophagic impairment [1, 2, 3, 4, 5, 6, 7, 8].

Autophagy is a primary cell response to stress and can be induced by starvation, endoplasmic reticulum (ER) stress, hypoxia, cytotoxicity, and infection (Figure 1). Sensation, initiation, and regulation of the autophagy–lysosomal pathway is controlled by the heterotrimeric serine/threonine kinase AMP (AMPK) and rapamycin complex 1 (mTORC1), either triggering or repressing autophagy and mitophagy. Unc-51-like kinase 1 (ULK1) is a primary initiating protein, as is mTORC1-supressed transcription factor EB (TFEB), which coordinates the synthesis of lysosomes and other essential proteins maintaining the autophagic flux [9, 10, 11, 12]. In addition, sirtuin-1—a class III deacetylase dependent on nicotinamide adenine dinucleotide (NAD+)—becomes a positive autophagy regulator, since it may also be considered a cellular sensor [13].

Figure 1.

Several cellular sensors regulate autophagic flux to maintain homeostasis.

This process is mainly regulated at a post-translational level, increasing mRNA expression of autophagy genes [14]. Under stress conditions, TFEB is translocated from cytosol to the nucleus, activating transcription of ATG genes and coordinating upregulation of the entire autophagy–lysosomal pathway [15].

Autophagy can be constitutive or inducible, rapidly adjusting to alterations within the internal and external environment of the cells. Autophagy serves as a housekeeping system, demonstrated by animal models deficient in autophagy-related genes (ATG). For example, deletion of specific neurons of ATG7 or 5 genes leads to postnatal neurodegeneration [16, 17].

Intrinsically, cellular sensors detect changes in levels of glucose, cytosolic Ca++, reactive oxygen species (ROS), and metabolic intermediates. Therefore, a decrease in glucose availability or impairment of mitochondrial respiration-compromising ATP production leads to an increase in the AMP/ADP ratio, activating the AMPK α subunit [10].

An example of extrinsic sensing occurs via drug-targetable mechanisms at the plasma membrane level. Tyrosine kinase receptors converge on mTOR, AMPK, or Beclin-1-Vps complex by modulating autophagy following growth factors [18, 19]. Even G-protein-coupled receptors (GPCRs) control autophagy via intracellular pathways that similarly modulate AMPK and mTOR [20, 21, 22].

This discussion includes a short overview of the more common types of autophagy and will highlight the role of autophagy in retinal diseases, with special attention to diabetic retinopathy.

Advertisement

2. Types of autophagy

There are three forms of autophagy previously described in the literature: macroautophagy, chaperone-mediated autophagy, and microautophagy (Figure 2).

Figure 2.

Types of autophagy. (1) Macroautophagy: initiation of autophagy through isolation membrane, extension of membrane, and closure forming the autophagosome. Finally, the autophagosome merges with lysosome. Lysosomal hydrolases digest the contents to recycling nutrients. (2) Chaperone-mediated autophagy: identification of KFERQ-motif by Hsc70. Transportation of damage protein to lysosome. Recognition and multimerization of LAMP-2. Damage proteins are translocated to inside of the lysosome to suffer the action of lysosomal hydrolases. (3) Microautophagy: recognition and internalization of cytoplasmatic component.

2.1 Macroautophagy

Usually known as autophagy, this intracellular pathway includes cytosolic components such as proteins, lipids, organelles, and parts of the nucleus [23, 24]. Autophagy was first described by Christian du Duve 50 years ago and has been highly preserved across the species. From beginning to end, the whole process is controlled by the ATG protein family, and more than 35 genes have been identified to orchestrate the process [25].

Autophagosome formation is the hallmark of this process. The well-coordinated process begins with an initiation phase, when ULK1 kinase forms a complex with ATG13, ATG10, and FIP200 (known as RB1CC1) at a specific cell site located in the perivacuolar region known as the phagophore assembly site (PAS). ULK1 kinase activity triggers the formation of the phosphoinositide 3-kinase (PI3K) complex, which favors the formation of phosphatidylinositol 3-phosphate, initiating the nucleation phase [26]. Ubiquitin-like conjugation systems are then activated, catalyzed by ATG7. ATG12 is conjugated to ATG5, then phosphatidylethanolamine to microtubule-associated protein 1A/1B-light chain 3 (LC3) through ATG7 kinase, forming an autophagosome bound to LC3 (also called LC3-II) [27, 28]. The late stage of autophagy is controlled by molecules that regulate maturation of the autophagosome, fusion with lysosomes, acidification of the inside compartment of the autophagosome components, and recycling of metabolites from the lysosomal compartment. This coordinated process—including a sequence of protein–protein and protein–lipid interaction—is a dynamic process, where the autophagosome formation, fusion to the lysosome, and digestion of the inside components occur in less than 10 minutes. Therefore, any sort of autophagy dysfunction (such as blockage of lysosomal fusion or lysosomal function impairment) may lead to accumulation of harmful damaged organelles and protein aggregates inside the cell [29] (Figure 2).

2.2 Chaperone-mediated autophagy

In chaperone-mediated autophagy, there is no reorganization of the lysosomal membrane. This selective autophagy is only described in mammals [30], which mediates delivery of specific proteins to the lysosome. The distinction occurs because the cytosolic proteins need to be degraded by the presence of a pentapeptide amino acid sequence, KFERQ. This sequence permits recognition of the target protein by a family of chaperones and co-chaperones: the heat shock cognate, 70-kDa (Hsc70)—the most abundant in the family. After recognition of the KFERQ sequence, Hsc70 presents the unfolded proteins to the lysosome, one by one, where they are recognized by the transmembrane domain of lysosome-associated membrane protein type 2A (LAMP2-A). After this, the multimerization of LAMP2-A occurs, allowing transportation of the substrate into the lysosome for degradation. At the end of this process, the LAMP2-A complex is disassembled, and the chaperone Hsp70 is released to start a new cycle [31].

2.3 Microautophagy

Microautophagy is not well described in mammalian cells. However, recent evidence has shown that there is recognition and internalization of small cytoplasmatic components in late endosomes. This type of autophagy requires the chaperone Hsc70. However, the microautophagy process is independent of the unfolding of KFERQ and the multimerization of LAMP2-A [32, 33].

2.4 Role of autophagy in disease development

Since the primary function of autophagy is to eliminate harmful components from cells (aggregated proteins, damaged organelles, and pathogens), malfunctioning of this mechanism implicit in diseases—such as Huntington’s and Parkinson’s diseases [34, 35]—results in protein accumulation.

In physiological conditions, autophagy is involved in cellular homeostasis, as demonstrated in heart diseases, as seen in heart failure and ischemia–reperfusion injuries [36]. In the pancreas, autophagy is required to maintain function of β cells, revealing significance in the pathogenesis of diabetes. Alterations in autophagy have also been described in a more complex model in cancer research: it can suppress tumors but also helps the tumor adapt to metabolic stress in its late stages [37].

Advertisement

3. Diabetic retinopathy

Diabetes mellitus is a public health issue, estimated to affect about 500 million people by 2035 [38]. Nearly 30% of patients are likely to suffer from retinal microvascular complications and 10% may experience visual threatening due to macular edema or proliferative diabetic retinopathy [39, 40].

Multiple mechanisms are triggered under hyperglycemic conditions (hexosamine and polyol pathways [41], synthesis de novo of diacylglycerol-PKC [42, 43], low grade oxidative stress [44, 45, 46], inflammation [47, 48, 49, 50, 51], and advanced glycation end products [52, 53]). Although vascular changes are presumed to be the hallmarks of DR, abnormalities in retinal function are detected in patients with diabetes who have good visual acuity [54, 55, 56, 57, 58, 59].

The characteristics of retinal neurodegeneration are apoptosis of neuro cells and dysfunction of glial cells—mainly Müller cells [29, 50, 60]. In microvascular disease of diabetic retinopathy, both inner and outer blood retinal barrier break down [61].

3.1 Autophagy in diabetic retinopathy

Since their pioneering studies, Remé et al. —describing the presence of active autophagy in photoreceptors during hibernation with a decreased number of mitochondria and organelles compared to animals in non-hibernating conditions—observed an increased number of autophagosomes [62]. These data show the pivotal role of autophagy in the retina, degrading cellular components (such as mitochondria) during hibernation.

Implications of autophagy in retinal ganglion cells (RGCs) attracted interest as a potential tool for neuroprotection in glaucoma. The first evidence of the cytoprotective role of autophagy in RGCs was shown by Rodríguez-Muela et al. using autophagy-deficient mice, which displayed increased axonal damage following optic nerve transection (ONT) models of optic neuropathy [63, 64, 65].

3.2 Autophagy in blood retinal barriers and implications on diabetic retinopathy

The main function of the blood-retina barrier (BRB) is maintenance of retinal homeostasis, regulating the transport of blood stream molecules to provide an appropriate supply for the neuroretina and to protect neural tissue against harmful agents present in the blood. The BRB is formed by two types of barriers: the inner blood-retina barrier (iBRB) and the outer blood-retina barrier (oBRB) [66].

Both outer and inner retinal barriers are affected by the toxic metabolic effects of hyperglycemia [67]. Alterations in the iBRB are more studied than the oBRB among the mechanisms of development and progression of DR [68, 69, 70]. The appropriated function of autophagy flux is important for maintenance of cellular viability and confers stress tolerance in retinal cells under adverse conditions such as DR [71].

Retinal endothelial cells of microcirculation of the retina form the iBRB. This barrier selectively allows passage of molecules from systemic circulation to retinal tissue. As a constituent of this barrier, there are tight junctions and adherens junctions such as zonula occludens-1 (ZO-1), occludin, VE-cadherin, and N-cadherin [72]. Endothelial cells are warped by pericytes, which are highly specialized. Pericytes play an essential role in the structure and stability of the iBRB, coordinating angiogenesis and vascular remodeling [73, 74].

Few articles have highlighted the autophagic process in retinal endothelial cells under diabetic conditions [75, 76]. Exposure to high glucose leads to an increase in retinal endothelial cell apoptosis, and this mechanism is mediated by the enhancement of ROS production. This phenomenon is correlated with a reduction in the AMPK pathway [76], which is well described as a direct activator of ULK-1 in the autophagy process [77]. Reestablishing the level of AMPK using specific activators—such as AICAR or antioxidant treatment—is effective in the protection of endothelial retinal cells from damage caused by diabetic conditions [75, 76]. A recent study from Niu et al. described the importance of the protective properties of metformin on retinal endothelial cells and human umbilical vascular endothelial cells (HUVECs) via autophagy in diabetic conditions. In this work, the authors showed that there was an increased LC3 puncta formation, which is an indicative of autophagy, in retinal vascular endothelium from db/db (diabetic) mice compared with control (non-diabetic) mice. This is indicative that metformin protects the retinal microvascular cells by diminishing LC3 formation. To further understand this mechanism, HUVECs were exposed to high levels of glucose and treated with metformin, resulting in a clear increase of LC3 formation. In HUVECs transfected with sh-PRKAA1/2 (AMP catalytic subunit), the protective effect of metformin was abrogated, indicating that metformin acts via AMPK activation [78] and improving autophagy in these cells.

The oBRB is a monolayer formed by retinal pigment epithelial cell layer that separates the neuro retina from choriocapillaris. Impairment of this barrier is implicated in diabetic retinopathy development [79, 80, 81]. The major functions of the oBRB are to provide glucose, fatty acids, and retinol to photoreceptors from choriocapillaris and reisomerise all-trans-retinal in 11-cis-retinal after photon absorption of the photoreceptor [66, 82, 83]. Therefore, any disturbance in this structure may have detrimental effects on the retina. A number of sight-threatening diseases display RPR dysfunction, such as age-related macular degeneration, proliferative vitreoretinopathy, and diabetic retinopathy [84].

It is well described in the literature that human retinal pigmented epithelial (RPE) immortalized cells (ARPE-19) exposed to high concentrations of glucose present molecular changes, including a decrease of proliferation, an increase in oxidative stress mediated by ROS production, and augmented lipid droplets and inflammation [85, 86, 87, 88]. These alterations can activate or repress the autophagic flux in RPE cells. Studies have shown that, until 48 hours of exposure to high glucose levels, ARPE-19 cells present an increase in lipid droplets, which can contribute to ROS production [71, 85, 89]. This increase in ROS production can initiate autophagy, enhancing the numbers of autophagosomes, increasing conversion of LC3-I to LC3-II, and decreasing levels of p62/SQSTM1 as a defense mechanism against damage caused by high glucose. However, Chen et al. found that an increase in autophagic flux promoted by high glucose cannot be maintained long-term. After 7 days in high glucose, ARPE-19 presented impairment in the degradation of p62/SQSTM1 and an increase in apoptotic cells. These findings indicated that autophagy was the first defense against oxidative stress in high-glucose conditions. In the long-term, this protective pathway became saturated and inefficient, thus contributing to RPE degeneration in DR [87].

Zhang et al. have shown that high glucose concentrations can attenuate the PINK1 and parkin pathways involved in controlling cellular mitophagy. Downregulation of mitophagy can lead to an increase in cellular stress levels because the biogenesis of mitochondria becomes compromised [90].

The role of autophagy in retinal diabetic complications is not simply a matter of inhibiting its initiation or progression. Inhibition of autophagy in ARPE-19 during its initial phase with 3-methyladenine (3-MA) or during the fusion of autophagosome and lysosome using bafilomycin aggravates oxidative stress and exacerbates secretion of the pro-inflammatory interleukin-1β promoted by high glucose [88]. The appropriated autophagic process is important as a mechanism of cell homeostasis in diabetic conditions.

3.3 Autophagy in Müller glial cells and implications in diabetic retinopathy pathogenesis

Müller cells are the predominant glial cell in the retina. Its unique morphology allows the Müller cell to directly interact with neighboring neural and vascular cells, expanding through the entire retina from the inner limiting membrane to the photoreceptor layer. Müller cells are closely related with vitreous, blood vessels, and sub retinal space. Each Müller cell interacts with one cone and 10 rods [91]. This configuration of Müller cells inside the retina explains the diversity of its function, responsible for the metabolic, functional, and structural support of the retina [92].

There are several functions attributed to Müller cells, such as the release of trophic factors [93, 94], neurotransmitter recycling [95], and phagocytosis of external photoreceptor segments [96, 97]. Müller cells, depending upon the stimulus (trauma, vascular, or metabolic), may react with phenotype changes called gliosis, which consist in adaptive morphological, biochemical, and physiological alterations. Among the more interesting biochemical changes in Müller cells are increased vascular endothelial growth factor (VEGF) [98] and glial fibrillary acidic protein (GFAP) production, both with pro-angiogenic and pro-inflammatory effects. Massive VEGF release is present in the proliferative stages of DR and diabetic macular edema, representing a major therapeutic target for pharmacological treatment of these devastating complications.

There are few studies showing the effects of high glucose on autophagy in retinal Müller cells. Devi et al. described the implications of autophagy dysfunction in the mechanisms of DR [99]. In their study, Müller cells exposed to high glucose conditions for 5 days displayed an increase of autophagosome and mitophagosome in the cytosol, suggesting high glucose conditions activated the autophagy process. Despite activation of the protective process (autophagy), they observed an association with an increased proapoptotic caspase-3, leading to programmed cell death. This scenario elucidates that diabetic conditions induce activation of autophagy followed by dysfunction, leading to cellular death.

In the previously published work addressing the mechanism by which Müller cells exposed to high glucose release high amounts of VEFG and trigger increased apoptosis, it was shown that the autophagic process was defective in Müller cells among diabetic conditions. In cells exposed to high glucose, autophagy markers—both early Beclin and late LC3-I and LC3-II—were increased, but p62/SQSTM1 accumulated in the cytosol compartment of Müller cells, accompanied by an increased apoptotic rate. To further understand how p62/SQSTM1 could modulate the autophagy and apoptosis in Müller cells exposed to high glucose, p62/SQSTM1 was suppressed. In this condition, there was less endoplasmic reticulum stress, lowering the interaction with caspase-8 and, by extension, less apoptosis. The presence of rapamycin, an mTOR blocker, triggered the formation of autophagosome and ameliorated the degradation of p62/SQSTM1. Rapamycin showed to improve proteolytic activity of the lysosome, reducing the release of VEGF. Corresponding findings were also demonstrated in models using diabetic animals. In the retinas of diabetic rats, there was a significant increase in p62/SQSTM1 accumulation, particularly in cells located in the inner nuclear layer [29]. Lysosomal impairment and autophagic flux dysfunction are early indicators of the pathogenesis of DR.

Advertisement

4. Conclusion

Diabetic retinopathy is a neurodegenerative disease presenting vascular changes in its late stages. Multiple factors are associated with the development and progression of DR. Recently, better understanding at cellular and molecular levels of its process has been identified through the pathways and intracellular signaling involved in cells exposed to diabetic conditions. This has allowed identification of new therapeutic approaches. Recent concepts of this disease have been analyzed here, with special focus on the process of autophagy using experimental models in different retinal cells targeted by hyperglycemia in the developmental stages of the disease.

References

  1. 1. Schapira AHV. Glucocerebrosidase and parkinson disease: Recent advances. Molecular and Cellular Neurosciences. 2015;66:37-42. DOI: 10.1016/j.mcn.2015.03.013
  2. 2. Kim MJ, Deng H-X, Wong YC, Siddique T, Krainc D. The Parkinson’s disease-linked protein TMEM230 is required for Rab8a-mediated secretory vesicle trafficking and retromer trafficking. Human Molecular Genetics. 2017;26(4):729-741. DOI: 10.1093/hmg/ddw413
  3. 3. Lee J-H, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, et al. Lysosomal proteolysis and autophagy require Presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141(7):1146-1158. DOI: 10.1016/j.cell.2010.05.008
  4. 4. Reddy PH, Yin X, Manczak M, Kumar S, Pradeepkiran JA, Vijayan M, et al. Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease. Human Molecular Genetics. 2018;27(14):2502-2516. DOI: 10.1093/hmg/ddy154
  5. 5. Scharl M, Wojtal KA, Becker HM, Fischbeck A, Frei P, Arikkat J, et al. Protein tyrosine phosphatase nonreceptor type 2 regulates Autophagosome formation in human intestinal cells. Inflammatory Bowel Diseases. 2012;18(7):1287-1302. DOI: 10.1002/ibd.21891
  6. 6. Vega-Rubín-de-Celis S, Zou Z, Fernández ÁF, Ci B, Kim M, Xiao G, et al. Increased autophagy blocks HER2-mediated breast tumorigenesis. Proceedings of the National Academy of Sciences. 2018;115(16):4176-4181. DOI: 10.1073/pnas.1717800115
  7. 7. Sumpter R, Sirasanagandla S, Fernández ÁF, Wei Y, Dong X, Franco L, et al. Fanconi anemia proteins function in Mitophagy and immunity. Cell. 2016;165(4):867-881. DOI: 10.1016/j.cell.2016.04.006
  8. 8. Lassen KG, McKenzie CI, Mari M, Murano T, Begun J, Baxt LA, et al. Genetic coding variant in GPR65 alters Lysosomal pH and links Lysosomal dysfunction with colitis risk. Immunity. 2016;44(6):1392-1405. DOI: 10.1016/j.immuni.2016.05.007
  9. 9. Fernández ÁF, Sebti S, Wei Y, Zou Z, Shi M, McMillan KL, et al. Disruption of the beclin 1–BCL2 autophagy regulatory complex promotes longevity in mice. Nature. 2018;558(7708):136-140. DOI: 10.1038/s41586-018-0162-7
  10. 10. Melendez A. Autophagy genes are essential for Dauer development and life-span extension in C. elegans. Science. 2003;301(5638):1387-1391. DOI: 10.1038/s41586-018-0162-7
  11. 11. Hars ES, Qi H, Jin SV, Cai L, Hu C, Liu LF. Autophagy Regulates Ageing in C. elegans. Autophagy. 2007;3(2):93-95. DOI: 10.4161/auto.3636
  12. 12. Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon CA. Role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genetics. 2008;4(2):e24. DOI: 10.1371/journal.pgen.0040024
  13. 13. Juhasz G, Erdi B, Sass M, Neufeld TP. Atg7-dependent autophagy promotes neuronal health, stress tolerance, and longevity but is dispensable for metamorphosis in drosophila. Genes & Development. 2007;21(23):3061-3066. DOI: 10.1101/gad.1600707
  14. 14. Feng Y, Yao Z, Klionsky DJ. How to control self-digestion: Transcriptional, post-transcriptional, and post-translational regulation of autophagy. Trends in Cell Biology. 2015;25(6):354-363. DOI: 10.1016/j.tcb.2015.02.002
  15. 15. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, et al. A gene network regulating Lysosomal biogenesis and function. Science. 2009;325(5939):473-477. DOI: 10.1126/science.1174447
  16. 16. Lipinski MM, Zheng B, Lu T, Yan Z, Py BF, Ng A, et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer’s disease. Proceedings of the National Academy of Sciences. 2010;107(32):14164-14169. DOI: 10.1016/j.cellsig.2013.06.013
  17. 17. Chen Y, Sawada O, Kohno H, Le YZ, Subauste C, Maeda T, et al. Autophagy protects the retina from light-induced degeneration. The Journal of Biological Chemistry. 2013;288(11):7506-7518. DOI: 10.1074/jbc.M112.439935
  18. 18. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, et al. FoxO3 coordinately activates protein degradation by the Autophagic/Lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metabolism. 2007;6(6):472-483. DOI: 10.1016/j.cmet.2007.11.004
  19. 19. Sarkis GJ, Ashcom JD, Hawdon JM, Jacobson LA. Decline in protease activities with age in the nematode caenorhabditis elegans. Mechanisms of Ageing and Development. 1988;45(3):191-201. DOI: 10.1016/0047-6374(88)90001-2
  20. 20. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, et al. The role of autophagy during the early neonatal starvation period. Nature. 2004;432(7020):1032-1036. DOI: 10.1038/nature03029
  21. 21. Kapahi P, Kaeberlein M, Hansen M. Dietary restriction and lifespan: Lessons from invertebrate models. Ageing Research Reviews. 2017;39:3-14. DOI: 10.1016/j.arr.2016.12.005
  22. 22. Mattison JA, Colman RJ, Beasley TM, Allison DB, Kemnitz JW, Roth GS, et al. Caloric restriction improves health and survival of rhesus monkeys. Nature Communications. 2017;8(1):14063. DOI: 10.1038/ncomms14063
  23. 23. Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nature Cell Biology. 2013;15(7):713-720. DOI: 10.1038/ncb2788
  24. 24. Dou Z, Xu C, Donahue G, Shimi T, Pan JA, Zhu J, et al. Autophagy mediates degradation of nuclear lamina. Nature. 2015;527(7576):105-109. DOI: 10.1038/nature15548
  25. 25. Ktistakis NT, Tooze SA. Digesting the expanding mechanisms of autophagy. Trends in Cell Biology. 2016;26(8):624-635. DOI: 10.1016/j.tcb.2016.03.006
  26. 26. Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M, et al. Mammalian autophagy: How does it work? Annual Review of Biochemistry. 2016;85(1):685-713. DOI: 10.1146/annurev-biochem-060815-014556
  27. 27. Choi AMK, Ryter SW, Levine B. Mechanisms of disease: Autophagy in human health and disease. The New England Journal of Medicine. 2013;368(7):651-662. DOI: 10.1056/NEJMra1205406
  28. 28. Suzuki H, Osawa T, Fujioka Y, Noda NN. Structural biology of the core autophagy machinery. Current Opinion in Structural Biology. 2017;43:10-17. DOI: 10.1016/j.sbi.2016.09.010
  29. 29. Lopes de Faria JM, Duarte DA, Montemurro C, Papadimitriou A, Consonni SR, Lopes de Faria JB. Defective autophagy in diabetic retinopathy. Investigative Ophthalmology & Visual Science. 2016;57(10):4356. DOI: 10.1167/iovs.16-19197
  30. 30. Arias E, Cuervo AM. Chaperone-mediated autophagy in protein quality control. Current Opinion in Cell Biology. 2011;23(2):184-189. DOI: 10.1016/j.ceb.2010.10.009
  31. 31. Orenstein SJ, Cuervo AM. Chaperone-mediated autophagy: Molecular mechanisms and physiological relevance. Seminars in Cell & Developmental Biology. 2010;21(7):719-726. DOI: 10.1074/jbc.R117.818237
  32. 32. Sahu R, Kaushik S, Clement CC, Cannizzo ES, Scharf B, Follenzi A, et al. Microautophagy of cytosolic proteins by late endosomes. Developmental Cell. 2011;20(1):131-139. DOI: 10.1016/j.devcel.2010.12.003
  33. 33. Tekirdag K, Cuervo AM. Chaperone-mediated autophagy and endosomal microautophagy: Jointed by a chaperone. The Journal of Biological Chemistry. 2018;293(15):5414-5424. DOI: 10.1074/jbc.R117.818237
  34. 34. Moloudizargari M, Asghari MH, Ghobadi E, Fallah M, Rasouli S, Abdollahi M. Autophagy, its mechanisms and regulation: Implications in neurodegenerative diseases. Ageing Research Reviews. 2017;40:64-74. DOI: 10.1016/j.arr.2017.09.005
  35. 35. Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, et al. Autophagy and Neurodegeneration: Pathogenic mechanisms and therapeutic opportunities. Neuron. 2017;93(5):1015-1034. DOI: 10.1016/j.neuron.2017.01.022
  36. 36. Lavandero S, Chiong M, Rothermel BA, Hill JA. Autophagy in cardiovascular biology. The Journal of Clinical Investigation. 2015;125(1):55-64. DOI: 10.1172/JCI73943
  37. 37. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Autophagy mediates tumor suppression via cellular senescence. Trends in Cell Biology. 2016;26(1):1-3. DOI: 10.1016/j.tcb.2015.11.001
  38. 38. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053. DOI: 10.2337/diacare.27.5.1047
  39. 39. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564. DOI: 10.2337/dc11-1909
  40. 40. Kempen JH, O’Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, et al. The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology. 2004;122(4):552-563. DOI: 10.1001/archopht.122.4.552
  41. 41. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. The Journal of Biological Chemistry. 2006;281(14):9307-9313. DOI: 10.1074/jbc.M600418200
  42. 42. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation Research. 2010;106(8):1319-1331. DOI: 10.1161/CIRCRESAHA.110.217117
  43. 43. Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications. Proceedings of the National Academy of Sciences. 2006;86(13):5141-5145. DOI: 10.1073/pnas.86.13.5141
  44. 44. Wu M, Yiang G, Lai T, Li C. The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxidative Medicine and Cellular Longevity. 2018;2018:1-12. DOI: 10.1155/2018/3420187
  45. 45. Rosales MAB, Silva KC, Duarte DA, Rossato FA, Lopes de Faria JB, Lopes de Faria JM. Endocytosis of tight junctions Caveolin Nitrosylation dependent is improved by cocoa via opioid receptor on RPE cells in diabetic conditions. Investigative Ophthalmology & Visual Science. 2014;55(9):6090. DOI: 10.1167/iovs.14-14234
  46. 46. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54(6):1615-1625. DOI: 10.3390/nu8090585
  47. 47. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. The Journal of Biological Chemistry. 1997;272(26):16498-16506. DOI: 10.1074/jbc.272.26.16498
  48. 48. Rajagopal R, Bligard GW, Zhang S, Yin L, Lukasiewicz P, Semenkovich CF. Functional deficits precede structural lesions in mice with high-fat diet-induced diabetic retinopathy. Diabetes. 2016;65:1-35. DOI: 10.2337/db15-1255
  49. 49. Shelton MD, Kern TS, Mieyal JJ. Glutaredoxin regulates nuclear factor κ-B and intercellular adhesion molecule in Müller cells: Model of diabetic retinopathy. The Journal of Biological Chemistry. 2007;282(17):12467-12474. DOI: 10.1074/jbc.M610863200
  50. 50. Duarte DA, Papadimitriou A, Gilbert RE, Thai K, Zhang Y, Rosales MAB, et al. Conditioned medium from early-outgrowth bone marrow cells is retinal protective in experimental model of diabetes. PLoS One. 2016;11(2):e0147978. DOI: 10.1371/journal.pone.0147978
  51. 51. Dátilo MN, Sant’Ana MR, Formigari GP, Rodrigues PB, de Moura LP, da Silva ASR, et al. Omega-3 from flaxseed oil protects obese mice against diabetic retinopathy through GPR120 receptor. Scientific Reports. 2018;8(1):14318. DOI: 10.1038/s41598-018-32553-5
  52. 52. Genuth S, Sun W, Cleary P, Gao X, Sell DR, Lachin J, et al. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes. 2015;64(1):266-278. DOI: 10.1007/s00726-010-0773-2
  53. 53. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced Glycation end products. The Journal of Biological Chemistry. 2001;276(47):43836-43841. DOI: 10.1074/jbc.M106534200
  54. 54. Hyvarärinen L, Laurinen P, Rovamo J. Contrast sensitivity in evaluation of visual impairment due to diabetes. Acta Ophthalmologica. 2009;61(1):94-101. DOI: 10.1111/j.1755-3768.1983.tb01399.x
  55. 55. Sokol S, Moskowitz A, Skarf B, Evans R, Molitch M, Senior B. Contrast sensitivity in diabetics with and without background retinopathy. Archives of Ophthalmology. 1985;103(1):51-54. DOI: 10.1001/archopht.1985.01050010055018
  56. 56. Hardy KJ, Lipton J, Scase MO, Foster DH, Scarpello JHB. Detection of colour vision abnormalities in uncomplicated type 1 diabetic patients with angiographically normal retinas. The British Journal of Ophthalmology. 1992;76(8):461-464. DOI: 10.1136/bjo.76.8.461
  57. 57. Bresnick GH. Electroretinographic oscillatory potentials predict progression of diabetic retinopathy. Archives of Ophthalmology. 1984;102(9):1307. DOI: 10.1167/iovs.04-1409
  58. 58. Lopes de Faria J, Katsumi O, Cagliero E, Nathan D, Hirose T. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefe's Archive for Clinical and Experimental Ophthalmology. 2001;239(9):643-648. DOI: 10.1007/s004170100268
  59. 59. Simó R, Hernández C. Neurodegeneration in the diabetic eye: New insights and therapeutic perspectives. Trends in Endocrinology and Metabolism. 2014;25(1):23-33. DOI: 10.1016/j.tem.2013.09.005
  60. 60. Duarte DA, Rosales MAB, Papadimitriou A, Silva KC, Amancio VHO, Mendonça JN, et al. Polyphenol-enriched cocoa protects the diabetic retina from glial reaction through the sirtuin pathway. The Journal of Nutritional Biochemistry. 2015;26(1):64-74. DOI: 10.1016/j.jnutbio.2014.09.003
  61. 61. Li PSH, Wong TH, Tang WWT, Lai JSM. Diabetic retinopathy. Hong Kong Practice. 2004;26(8):346-353. DOI: 10.1038/nrdp.2016.12
  62. 62. Remé CE, Young RW. The effects of hibernation on cone visual cells in the ground squirrel. Investigative Ophthalmology and Visual Science. 1977;16(9):815-840
  63. 63. Rodríguez-Muela N, Germain F, Mariño G, Fitze PS, Boya P. Autophagy promotes survival of retinal ganglion cells after optic nerve axotomy in mice. Cell Death and Differentiation. 2012;19(1):162-169. DOI: 10.1038/cdd.2011.88
  64. 64. Rodríguez-Muela N, Boya P. Axonal damage, autophagy and neuronal survival. Autophagy. 2012;8(2):286-288. DOI: 10.4161/auto.8.2.18982
  65. 65. Kurz T, Karlsson M, Brunk UT, Nilsson SE, Frennesson C. ARPE-19 retinal pigment epithelial cells are highly resistant to oxidative stress and exercise strict control over their lysosomal redox-active iron. Autophagy. 2009;5(4):494-501. DOI: 10.4161/auto.5.4.7961
  66. 66. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. European Journal of Ophthalmology. 2011;21(Suppl 6):3-9. DOI: 10.5301/EJO.2010.6049
  67. 67. Di Rosa M, Distefano G, Gagliano C, Rusciano D, Malaguarnera L. Autophagy in diabetic retinopathy. Current Neuropharmacology. 2016;14(8):810-825. DOI: 10.2174/1570159X14666160321122900
  68. 68. Rübsam A, Parikh S, Fort P. Role of inflammation in diabetic retinopathy. International Journal of Molecular Sciences. 2018;19(4):942. DOI: 10.3390/ijms19040942
  69. 69. Díaz-Coránguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: Cellular basis and development. Vision Research. 2017;139:123-137. DOI: 10.1016/j.visres.2017.05.009
  70. 70. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: More than meets the eye. Survey of Ophthalmology. 2002;47:S253-S262. DOI: 10.1016/S0039-6257(02)00387-9
  71. 71. Huang C, Lu H, Xu J, Yu H, Wang X, Zhang X. Protective roles of autophagy in retinal pigment epithelium under high glucose condition via regulating PINK1/Parkin pathway and BNIP3L. Biological Research. 2018;51(1):22. DOI: 10.1186/s40659-018-0169-4
  72. 72. Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, et al. Mechanisms of macular edema: Beyond the surface. Progress in Retinal and Eye Research. 2018;63:20-68. DOI: 10.1016/j.preteyeres.2017.10.006
  73. 73. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell and Tissue Research. 2003;314(1):15-23. Available from: http://link.springer.com/10.1007/s00441-003-0745-x
  74. 74. Park DY, Lee J, Kim J, Kim K, Hong S, Han S, et al. Plastic roles of pericytes in the blood–retinal barrier. Nature Communications. 2017;8(1):15296. DOI: 10.1007/s00441-003-0745-x
  75. 75. Mao XB, You ZP, Wu C, Huang J. Potential suppression of the high glucose and insulin-induced retinal neovascularization by Sirtuin 3 in the human retinal endothelial cells. Biochemical and Biophysical Research Communications. 2017;482(2):341-345. DOI: 10.1016/j.bbrc.2016.11.065
  76. 76. Li J, Yu S, Ying J, Shi T, Wang P. Resveratrol prevents ROS-induced apoptosis in high glucose-treated retinal capillary endothelial cells via the activation of AMPK/Sirt1/PGC-1 α pathway. Oxidative Medicine and Cellular Longevity. 2017;2017:1-10. DOI: 10.1155/2017/7584691
  77. 77. Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature Cell Biology. 2011;13(2):132-141. DOI: 10.1038/ncb2152
  78. 78. Niu C, Chen Z, Kim KT, Sun J, Xue M, Chen G, et al. Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the hedgehog pathway. Autophagy. 2019;15(5):843-870. DOI: 10.1080/15548627.2019.1569913
  79. 79. Simó R, Villarroel M, Corraliza L, Hernández C, Garcia-Ramírez M. The retinal pigment epithelium: Something more than a constituent of the blood-retinal barrier-implications for the pathogenesis of diabetic retinopathy. Journal of Biomedicine and Biotechnology. 2010;2010:190724. DOI: 10.1155/2010/190724
  80. 80. Xu H-Z, Le Y-Z. Significance of outer blood–retina barrier breakdown in diabetes and ischemia. Investigative Ophthalmology & Visual Science. 2011;52(5):2160. DOI: 10.1167/iovs.10-6518
  81. 81. Xia T, Rizzolo LJ. Effects of diabetic retinopathy on the barrier functions of the retinal pigment epithelium. Vision Research. 2017;139:72-81. DOI: 10.1016/j.visres.2017.02.006
  82. 82. Strauss O. The retinal pigment epithelium in visual function. Physiological Reviews. 2005;85(3):845-881. DOI: 10.1152/physrev.00021.2004
  83. 83. Amram B, Cohen-Tayar Y, David A, Ashery-Padan R. The retinal pigmented epithelium – From basic developmental biology research to translational approaches. The International Journal of Developmental Biology. 2017;61(3-4-5):225-234. DOI: 10.1387/ijdb.160393ra
  84. 84. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. The American Journal of Pathology. 1989;134(2):231-235
  85. 85. Zhang W, Song J, Zhang Y, Ma Y, Yang J, He G, et al. Intermittent high glucose-induced oxidative stress modulates retinal pigmented epithelial cell autophagy and promotes cell survival via increased HMGB1. BMC Ophthalmology. 2018;18(1):192. DOI: 10.1016/j.biopha.2019.01.034
  86. 86. Boya P, Esteban-Martínez L, Serrano-Puebla A, Gómez-Sintes R, Villarejo-Zori B. Autophagy in the eye: Development, degeneration, and aging. Progress in Retinal and Eye Research. 2016;55:206-245. DOI: 10.1016/j.preteyeres.2016.08.001
  87. 87. Chen Q , Tang L, Xin G, Li S, Ma L, Xu Y, et al. Oxidative stress mediated by lipid metabolism contributes to high glucose-induced senescence in retinal pigment epithelium. Free Radical Biology & Medicine. 2019;130:48-58. DOI: 10.1016/j.freeradbiomed.2018.10.419
  88. 88. Shi H, Zhang Z, Wang X, Li R, Hou W, Bi W, et al. Inhibition of autophagy induces IL-1β release from ARPE-19 cells via ROS mediated NLRP3 inflammasome activation under high glucose stress. Biochemical and Biophysical Research Communications. 2015;463(4):1071-1076. DOI: 10.1016/j.bbrc.2015.06.060
  89. 89. Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: The clash between damage and metabolic needs. Cell Death and Differentiation. 2015;22(3):377-388. DOI: 10.1038/cdd.2014.150
  90. 90. Zhang Y, Xi X, Mei Y, Zhao X, Zhou L, Ma M, et al. High-glucose induces retinal pigment epithelium mitochondrial pathways of apoptosis and inhibits mitophagy by regulating ROS/PINK1/Parkin signal pathway. Biomedicine & Pharmacotherapy. 2019;111:1315-1325. DOI: 10.1016/j.biopha.2019.01.034
  91. 91. Reichenbach A, Bringmann A. Müller Cells in the Healthy and Diseased Retina. Müller Cells in the Healthy and Diseased Retina. New York, NY: Springer New York; 2010. DOI: 10.1007/978-1-4419-1672-3
  92. 92. Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC. Glia–neuron interactions in the mammalian retina. Progress in Retinal and Eye Research. 2016;51:1-40. DOI: 10.1016/j.preteyeres.2015.06.003
  93. 93. Pow DV, Crook DK. Direct immunocytochemical evidence for the transfer of glutamine from glial cells to neurons: Use of specific antibodies directed against thed-stereoisomers of glutamate and glutamine. Neuroscience. 1996;70(1):295-302. DOI: 10.1016/0306-4522(95)00363-N
  94. 94. Powell C, Grant AR, Cornblath E, Goldman D. Analysis of DNA methylation reveals a partial reprogramming of the Muller glia genome during retina regeneration. Proceedings of the National Academy of Sciences. 2013;110(49):19814-19819. DOI: 10.1073/pnas.1312009110
  95. 95. Schütte M, Werner P. Redistribution of glutathione in the ischemic rat retina. Neuroscience Letters. 1998;246(1):53-56. DOI: 10.1016/S0304-3940(98)00229-8
  96. 96. Long KO, Fisher SK, Fariss RN, Anderson DH. Disc shedding and autophagy in the cone-dominant ground squirrel retina. Experimental Eye Research. 1986;43(2):193-205. DOI: 10.1016/S0014-4835(86)80087-2
  97. 97. Wang JS, Kefalov VJ. The cone-specific visual cycle. Progress in Retinal and Eye Research. 2011;30(2):115-128. DOI: 10.1016/j.preteyeres.2010.11.001
  98. 98. Bai Y, Ma J, Guo J, Wang J, Zhu M, Chen Y, et al. Müller cell-derived VEGF is a significant contributor to retinal neovascularization. The Journal of Pathology. 2009;219(4):446-454. DOI: 10.1002/path.2611
  99. 99. Devi TS, Lee I, Hüttemann M, Kumar A, Nantwi KD, Singh LP. TXNIP links innate host defense mechanisms to oxidative stress and inflammation in retinal Muller glia under chronic hyperglycemia: Implications for diabetic retinopathy. Experimental Diabetes Research. 2012;2012:1-19. DOI: 10.1155/2012/438238

Written By

Jacqueline M. Lopes de Faria and Marcella Neves Dátilo

Submitted: 24 July 2019 Reviewed: 26 August 2019 Published: 06 November 2019